R. Ghori

发表

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

S. Jagannath, S. Lonial, A. Oriol, 2019, The Lancet. Haematology.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Juanita Lopez, S. Im, H. Chung, 2021, Journal of Clinical Oncology.

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

D. Siegel, N. Munshi, D. Reece, 2019, British journal of haematology.

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

P. Ascierto, A. Ribas, M. Del Vecchio, 2021, European journal of cancer.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.

L. Diaz, P. Ascierto, Y. Bang, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

P. Ascierto, A. Ribas, H. Schmidt, 2020, Journal for ImmunoTherapy of Cancer.

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

Tae Won Kim, H. Chung, N. Penel, 2022, Journal of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Pembrolizumab (pembro) plus dabrafenib (dab) and trametinib (tram) in BRAFV600E/K-mutant melanoma: Long-term follow-up of KEYNOTE-022 parts 1, 2, and 3.

P. Ascierto, A. Ribas, H. Schmidt, 2022, Journal of Clinical Oncology.

Pembrolizumab combined with carfilzomib and low‐dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE‐023 study

P. Moreau, J. S. San Miguel, P. Marinello, 2021, British journal of haematology.

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase II LEAP-005 study.

Tae Won Kim, H. Chung, N. Penel, 2021 .

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

Juanita Lopez, S. Im, H. Chung, 2022, Journal of Clinical Oncology.

KEYNOTE-022 Part 3: Phase II randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (Pembro) or placebo (PBO) for BRAF-mutant advanced melanoma.

P. Ascierto, N. Ibrahim, A. Ribas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Juanita Lopez, H. Chung, A. Hendifar, 2021 .

Pembrolizumab (Pembro) plus lenalidomide (Len) and low-dose dexamethasone (Dex) for relapsed/refractory multiple myeloma (RRMM): Efficacy and biomarker analyses.

J. Miguel, N. Munshi, R. Mogg, 2017 .

Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

I. Flinn, F. Awan, T. Phillips, 2022, Blood.

Abstract PS12-07: Lenvatinib plus pembrolizumab for previously treated, advanced triple-negative breast cancer: Early results from the multicohort phase 2 LEAP-005 study

Juanita Lopez, S. Im, H. Chung, 2021 .

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

Juanita Lopez, H. Chung, A. Hendifar, 2022, Journal of Clinical Oncology.

LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours

Juanita Lopez, E. Castañón, M. Doherty, 2020 .

A phase 3 randomized study of pembrolizumab (pembro) plus lenalidomide (len) and low-dose dexamethasone (Rd) versus Rd for newly diagnosed and treatment-naive multiple myeloma (MM): KEYNOTE-185.

Jason J. Z. Liao, S. Jagannath, S. Lonial, 2018 .

Publisher Correction: Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Network Boston.

Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma

R. Fisher, A. Ribas, F. Hodi, 2019, Nature Medicine.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma

P. Ascierto, R. Fisher, A. Ribas, 2019, Nature Medicine.